These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

262 related articles for article (PubMed ID: 24024757)

  • 1. Randomised clinical trial: sodium alginate oral suspension is non-inferior to omeprazole in the treatment of patients with non-erosive gastroesophageal disease.
    Chiu CT; Hsu CM; Wang CC; Chang JJ; Sung CM; Lin CJ; Chen LW; Su MY; Chen TH
    Aliment Pharmacol Ther; 2013 Nov; 38(9):1054-64. PubMed ID: 24024757
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy of adding sodium alginate to omeprazole in patients with nonerosive reflux disease: a randomized clinical trial.
    Manabe N; Haruma K; Ito M; Takahashi N; Takasugi H; Wada Y; Nakata H; Katoh T; Miyamoto M; Tanaka S
    Dis Esophagus; 2012 Jul; 25(5):373-80. PubMed ID: 22050449
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Randomised clinical trial: the clinical efficacy and safety of an alginate-antacid (Gaviscon Double Action) versus placebo, for decreasing upper gastrointestinal symptoms in symptomatic gastroesophageal reflux disease (GERD) in China.
    Sun J; Yang C; Zhao H; Zheng P; Wilkinson J; Ng B; Yuan Y
    Aliment Pharmacol Ther; 2015 Oct; 42(7):845-54. PubMed ID: 26228097
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Clinical Efficacy of a Pure Alginate Formulation (Lamina G) for Controlling Symptoms in Individuals with Reflux Symptoms: A Randomized Clinical Study.
    Kim JH; Lee YC; Kim EH; Park JC; Shin SK; Lee SK; Jung DH; Park JJ; Youn YH; Park H
    Gut Liver; 2019 Nov; 13(6):642-648. PubMed ID: 30970442
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gaviscon® vs. omeprazole in symptomatic treatment of moderate gastroesophageal reflux. a direct comparative randomised trial.
    Pouchain D; Bigard MA; Liard F; Childs M; Decaudin A; McVey D
    BMC Gastroenterol; 2012 Feb; 12():18. PubMed ID: 22361121
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tailored therapy guided by multichannel intraluminal impedance pH monitoring for refractory non-erosive reflux disease.
    Ranaldo N; Losurdo G; Iannone A; Principi M; Barone M; De Carne M; Ierardi E; Di Leo A
    Cell Death Dis; 2017 Sep; 8(9):e3040. PubMed ID: 28880273
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative Study of Alginate and Omeprazole in Symptomatic Treatment of Non-erosive Gastroesophageal Reflux Disease.
    Saifullah AM; Ahmed F; Shil BC; Banik RK; Saha SK; Chowdhury M; Haque A; Alam MS; Akhter A
    Mymensingh Med J; 2018 Oct; 27(4):771-775. PubMed ID: 30487493
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of omeprazole for the treatment of symptomatic acid reflux disease without esophagitis.
    Richter JE; Peura D; Benjamin SB; Joelsson B; Whipple J
    Arch Intern Med; 2000 Jun; 160(12):1810-6. PubMed ID: 10871975
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Randomized clinical trial: a double-blind, placebo-controlled study to assess the clinical efficacy and safety of alginate-antacid (Gaviscon Double Action) chewable tablets in patients with gastro-oesophageal reflux disease.
    Wilkinson J; Wade A; Thomas SJ; Jenner B; Hodgkinson V; Coyle C
    Eur J Gastroenterol Hepatol; 2019 Jan; 31(1):86-93. PubMed ID: 30272584
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effectiveness of add-on therapy with domperidone vs alginic acid in proton pump inhibitor partial response gastro-oesophageal reflux disease in systemic sclerosis: randomized placebo-controlled trial.
    Foocharoen C; Chunlertrith K; Mairiang P; Mahakkanukrauh A; Suwannaroj S; Namvijit S; Wantha O; Nanagara R
    Rheumatology (Oxford); 2017 Feb; 56(2):214-222. PubMed ID: 27179107
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of wu chu yu tang on gastroesophageal reflux disease: Randomized, double-blind, placebo-controlled trial.
    Shih YS; Tsai CH; Li TC; Yu CJ; Chou JW; Feng CL; Wang KT; Lai HC; Hsieh CL
    Phytomedicine; 2019 Mar; 56():118-125. PubMed ID: 30668332
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Randomized controlled trial: roxatidine vs omeprazole for non-erosive reflux disease.
    Nakamura K; Akiho H; Ochiai T; Motomura Y; Higuchi N; Okamoto R; Matsui N; Yasuda D; Akahoshi K; Kabemura T; Ihara E; Harada N; Ito T; Takayanagi R
    Hepatogastroenterology; 2010; 57(99-100):497-500. PubMed ID: 20698216
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gastroesophageal reflux in pregnancy: a systematic review on the benefit of raft forming agents.
    Quartarone G
    Minerva Ginecol; 2013 Oct; 65(5):541-9. PubMed ID: 24096290
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Alginate therapy is effective treatment for gastroesophageal reflux disease symptoms: a systematic review and meta-analysis.
    Leiman DA; Riff BP; Morgan S; Metz DC; Falk GW; French B; Umscheid CA; Lewis JD
    Dis Esophagus; 2017 Feb; 30(2):1-8. PubMed ID: 27671545
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Randomized controlled trial comparing the efficacy of mosapride plus omeprazole combination therapy to omeprazole monotherapy in gastroesophageal reflux disease.
    Yamaji Y; Isomura Y; Yoshida S; Yamada A; Hirata Y; Koike K
    J Dig Dis; 2014 Sep; 15(9):469-76. PubMed ID: 24957863
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rabeprazole, 20 mg once daily or 10 mg twice daily, is equivalent to omeprazole, 20 mg once daily, in the healing of erosive gastrooesophageal reflux disease.
    Delchier JC; Cohen G; Humphries TJ
    Scand J Gastroenterol; 2000 Dec; 35(12):1245-50. PubMed ID: 11199361
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Randomised clinical trial: relief of upper gastrointestinal symptoms by an acid pocket-targeting alginate-antacid (Gaviscon Double Action) - a double-blind, placebo-controlled, pilot study in gastro-oesophageal reflux disease.
    Thomas E; Wade A; Crawford G; Jenner B; Levinson N; Wilkinson J
    Aliment Pharmacol Ther; 2014 Mar; 39(6):595-602. PubMed ID: 24471505
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Randomised clinical trial: alginate (Gaviscon Advance) vs. placebo as add-on therapy in reflux patients with inadequate response to a once daily proton pump inhibitor.
    Reimer C; Lødrup AB; Smith G; Wilkinson J; Bytzer P
    Aliment Pharmacol Ther; 2016 Apr; 43(8):899-909. PubMed ID: 26909885
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Distinguishing the impact of dexlansoprazole on heartburn vs. regurgitation in patients with gastro-oesophageal reflux disease.
    Peura DA; Pilmer B; Hunt B; Mody R; Perez MC
    Aliment Pharmacol Ther; 2013 Nov; 38(10):1303-11. PubMed ID: 24118079
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Challenges of correlating pH change with relief of clinical symptoms in gastro esophageal reflux disease: a phase III, randomized study of Zegerid versus Losec.
    Walker D; Ng Kwet Shing R; Jones D; Gruss HJ; Reguła J
    PLoS One; 2015; 10(2):e0116308. PubMed ID: 25706883
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.